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Abstract
Background: RNA interference (RNAi) emerges as a powerful tool to induce loss-of-function phenotypes. In the
context of the brain, gene manipulation is best targeted to specific subsets of cells in order to achieve a
physiologically relevant outcome. Polymerase II-based viral expression systems can be used to cell-specifically
express constructs incorporating flanking and loop sequences from endogenous microRNA (miRNA), which directs
the designed hairpins into the endogenous gene silencing machinery. While many studies have documented non-
cell-selective gene knock-down in the brain, it has not been tested whether different cell types or different areas of
the central nervous system (CNS) are equally amenable to this approach. We have evaluated this issue using a
tetracycline (Tet)-controllable and cell-specific miRNA 30 (miR30)-based short hairpin (shRNA) interference system.
Results: To achieve targeted expression two cell type-specific promoters were used; the enhanced compact glial
fibrillary acidic protein (GfaABC1D) promoter and the enhanced human synapsin-1 (SYN) promoter. Powerful
luciferase (Luc) and the neuronal isoform of nitric oxide synthase (nNOS) gene knock-down were achieved both in
vitro and in vivo. Administration of doxycycline (Dox) abrogated gene silencing. However, the efficacy of gene
knock-down in both neurones and astrocytes in the hippocampus (HIP) was lower than that in the dorsal vagal
complex of the brainstem (DVC). This was not due to regional differences in the expression of the the key enzymes
involved in miRNA processing.
Conclusions: The results from the presented experiments demonstrated that selective gene knock-down in
subsets of brain cells is achievable. However, there are some presently unknown regional factors which affect
either the processing of miRNA-based cassettes or their potency for gene silencing.
Background
RNAi is a conserved regulatory process that mediates
sequence-specific post-transcriptional gene silencing in a
variety of species [1,2]. The RNAi technique has become
a potent experimental tool for functional analysis of
genes and is believed to have significant therapeutic
potential [3-6]. In the context of the brain, where
numerous cell types with different functions are inter-
mixed, gene knock-down targeted to a cellular specified
phenotype in most cases would be preferable, in order
to achieve a physiologically or medically relevant out-
come [7,8]. Within vector-based RNAi systems, miRNA-
based cassettes, in which shRNA is embedded in a pre-
cursor miRNA context, are particularly attractive [9-12].
Endogenous miRNAs are transcribed predominantly by
polymerase II (Pol II) promoters as long primary miR-
NAs transcripts (pri-miRNAs) that are subsequently
processed into precursor miRNAs (pre-miRNAs) and
eventually incorporated into the RNA-induced silencing
complex (RISC) to mediate silencing of the target gene
([9]). Vectors can be made to mimic naturally occurring
miRNAs whereby a designed pre-miRNA is embedded
in an authentic miRNA context enabling its entry into
the endogenous miRNA/RNAi pathway [9,11,13,14].
The value of this approach was demonstrated by Steg-
meier et al who achieved an effective knock-down with
only a single viral genome per cell [15]. This is an
important feature given that it is hard to achieve high
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large libraries of pre-designed constructs of this type are
commercially available from OpenBiosystems and Invi-
trogen. Typically, in these constructs the miRNA-like
motifs are fused to the end of a sequence encoding a
fluorescent protein, giving rise to a transcript which
encodes both the pre-miRNA and the reporter gene. As
this is a Pol II- driven system it can be controlled by a
tetracycline (or its analogue Dox)-responsive promoter
element (Tre) as used in many viral systems [16-18]. If
expression of the transactivator such as the Tet-off
transactivator (tTA) is cell type specific, this would
allow targeting gene knock-down to a specific cell type.
A st h es a m eg e n ef r e q u e n t l yc o - e x i s t si nb o t hn e u r o n e s
and astrocytes in the brain and may have different or
even opposite functions, cell-selective gene manipulation
has obvious advantages. In addition, for most experi-
mental and potential clinical applications, viral gene
knock-down might be most advantageous if targeted to
a selected brain region(s). It is usually assumed that the
mechanisms of miRNA-mediated gene knock-down are
ubiquitous and operate constitutively in various tissues
[3,19-21]. However, concerning the brain, it has not yet
been tested whether the same gene knock-down cassette
is equally effective in different areas of the central ner-
vous system (CNS).
There are two main objectives for this study: Firstly,
we asked whether cell-specific and Dox-controllable
gene knock-down can be achieved in both astrocytes
and neurones. Secondly, we compared the efficacy of
gene knock-down in two very different areas of the
CNS, an evolutionary “old” part of the brain within the
medulla oblongata involved with the control of various
autonomic functions and a much “younger” part of the
brain, the hippocampus (HIP ) .T ot h i se n d ,w ec o n -
structed a binary Dox-controllable and cell-specific
miR30-based RNAi system to express shRNAs targeting
a reporter gene for Luc and an endogenous gene for
nNOS. Luc was chosen as it allowed a quantifiable
assessment of the efficacy of gene knock-down at the
protein level. Furthermore, Luc quantification is reliable
and technically straightforward. nNOS was chosen as a
typical neuronal protein which is expressed in both
areas of the brain we chose to study at moderate levels
[22-25]. In these constructs gene targeting sequences
were embedded in the precursor miRNA context
derived from miR30, one of the most well-studied
miRNA in mammals. This construct was fused to the 3’
end of the GFP sequence and placed under control of
the Tre promoter within a lentiviral vector (LVV) back-
bone. To drive its expression in a cell-specific manner it
was co-applied with the other LVV expressing Tet-off
transactivator tTA using either GfaABC1D promoter for
astrocytes or SYN promoter for neurones, both
promoters were transcriptionally enhanced using
previously published approaches [26]. This yielded in a
binary system which was both, cell-specific and Dox-
controllable.
We demonstrate that significant knock-down can be
achieved in a cell-selective and Dox-controllable manner
for both an exogenous and endogenous targeted gene.
However, there are major regional differences in the
efficacy of the same gene knock-down cassette, which
cannot be explained by the differential expression of the
main known proteins involved in miRNA processing.
Methods
LVVs used in this study
Six LVVs were constructed for this study (Figure 1).
(1) LV-Tretight-GFP-miR30-shRNA/Luc where the GFP
sequence is followed by a miR30-embedded anti-Luc
hairpin under the control of the Tretight promoter;
(2) LV-Tretight-GFP-miR30-shRNA/nNOS, in which the
GFP sequence is followed by a miR30-embedded anti-
nNOS hairpin under the control of the Tretight promo-
ter; (3) LV-GfaABC1D-Luc where the Luc gene is
expressed by the astrocytic GfaABC1D promoter;
(4) LV-SYN-Luc, in which the Luc gene is expressed by
the neuronal SYN promoter; (5) LV-mCMV/SYN-tTA
where the tTA gene expression is under the control of
the enhanced SYN promoter by the bidirectional
transcriptional amplification strategy [26]; and (6) LV-
mCMV/GfaABC1D-tTA in which the tTA gene expres-
sion is under the control of the enhanced GfaABC1D
promoter by the bidirectional transcriptionally amplifica-
tion strategy. The Luc targeting shRNA sequence was
provided by Dr. M.Z. Li (Howard Hughes Medical Insti-
tute, Boston) and the nNOS targeting sequence was
designed by using the RNAi design algorithm at http://
katahdin.cshl.org/siRNA/RNAi.cgi?type=shRNA and
kindly provided by Dr. Luna Benvenisti (Zarom Teva
Pharmaceutical Industries, USA). LV-GfaABC1D-Luc
and LV-SYN-Luc served as sources of Luc in either an
astrocyte- or neurone-specific manner. Additionally LV-
SYN-WPRE and LV-GfaABC1D-WPRE (unpublished
constructs in our lab, not illustrated) worked as control
vectors to balance the total load of viral particles into
cells or animal tissues.
Plasmid construction
All the LVV plasmids were based on the improved lenti-
viral shuttle vector pTYF-SW-Linker backbone using
standard cloning procedures [27]. To generate the LV-
Tretight-GFP-miR30-shRNA/Luc shuttle vector, we
excised the Tretight fragment containing the modified
Tet-responsive promoter from pTRE-Tight-DsRed2
(Clontech) and inserted it into the pTYF-SW Linker
and cloned, into the obtained vector, PCR product of
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GFP-FF3 (kindly provided by F. Stegmeier, Harvard
Medical School) downstream of Tretight promoter. To
construct the LV-Tretight-GFP-miR30-shRNA/nNOS
shuttle vector, we replaced the Luc shRNA sequence in
the LV-Tretight-GFP-miR30-shRNA/Luc shuttle vector
w i t ht h en N O Ss h R N A .W eo b t a i n e dL V - G f aA B C 1D-
Luc and LV-SYN-Luc shuttle vectors by replacing EGFP
in pTYF-1×GfaABC1D-EGFP and pTYF-1×SYN-EGFP
[26] with the Luc cDNA from the pGL3-Basic vector
(Promega) respectively. LV-mCMV/GfaABC1D-tTA and
LV-mCMV/SYN-tTA shuttle vectors were both pro-
duced by replacing EGFP in pTYF-mCMV/SYN-EGFP
and pTYF-mCMV/GfaABC1D-EGFP [26] with the tTA
cDNA from the LV-1×SYN-tTA shuttle vector [7].
LVV production
The LVV system used in this study is derived from
HIV-1 and pseudotyped with the vesicular stomatitis
virus coat [28]. LVV stocks were produced by transient
co-transfection of the shuttle plasmids, the packaging
vector pNHP, and the envelope plasmid pHEF-VSVG in
HEK293FT cells. Viral concentration and titration were
carried out as described earlier [28].
Cell culture and in vitro LVV vector transduction
The in vitro transduction experiments were carried out
in a neurone-derived rat pheochromocytoma PC12 cell
line and a 1321N1 glial cell line from human brain
astrocytoma. PC12 cells were grown in Dulbecco’s mod-
ified Eagle’s medium (DMEM) supplemented with 10%
heat-inactivated fetal bovine serum (FBS) and 5% horse
serum. 1321N1 cells were cultured in DMEM supple-
mented with 10% heat-inactivated FBS. The cells were
split and plated in 24-well plates at a cell density of 5 ×
10
4 per well with 0.5 ml culture medium. After 24 h,
cells were transduced overnight with appropriate LVVs
i nt h ep r e s e n c eo fp o l y b r e n e( 8μg/ml). The ratio for
three vectors in all cotransfections was fixed to 1:1:1
and the total viral MOI per well was fixed to 5. Cells
were then washed in phosphate-buffered saline (PBS)
and cultured in full media for a further 48 h. For each
virus combination, 3 wells were transduced. At the end
of the incubation, cells were washed and permeabilized
with 100 μl of reporter cell lysis buffer (Promega) for
Luc activity assay or 100 μl of radioimmunoprecipitation
(RIPA) buffer (50 mM Tris, 1% NP-40, 1% Sodium
Deoxycholate, 0.1% SDS, 150 mM NaCl, 1 mM EDTA,
pH 7.5) plus a protease inhibitor cocktail (Sigma) for
Figure 1 Schematic representation of lentiviral vectors used in the current study. LTR, lentiviral long terminal repeats; Tretight, a modified
tetracycline and Dox-responsive promoter derived from pTRE-tight (Clontech); GFP, green fluorescence protein; miR30-shRNA/Luc, miR30-based
shRNA targeting firefly Luc gene; miR30-shRNA/nNOS, miR30-based shRNA targeting rat neuronal nitric oxide synthase gene; Luc, firefly Luc
gene; GfaABC1D, a compact glial fibrillary acidic protein promoter (690 bp); SYN, human synapsin 1 promoter (470 bp); mCMV, minimal CMV
core promoter (65 bp); GAL4BDp65, a chimeric transactivator consisting of a part of the transactivation domain of the murine NF-Bp65 protein
fused to the DNA binding domain of GAL4 protein from yeast; WPRE, woodchuck hepatitis post-transcriptional regulatory element.
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be kept at -80°C until processing.
In vivo stereotaxic injections
All experiments were carried out in accordance with the
Animals Scientific Procedures Act 1986. The animals were
housed individually, allowed normal rat chow and drinking
water ad libitum, and kept on a 12-hour light/12-hour
dark cycle. Briefly, adult male Wistar rats (200~250 g)
were anaesthetized with ketamine and medetomidine
intramuscularly and their heads mounted securely in a
stereotaxic frame. LVV were microinjected stereotaxically
into either the DVC including the hypoglossal motor
nucleus as before [8] or HIP at the following coordinates:
anterior, -4.4 mm; lateral, +3.2 mm; ventral, -2.5 mm from
the surface of the dura as described in [29]. A total of six
microinjections of viral vectors were made bilaterally for
both DVC and HIP injections. In cases where three viral
vectors had to be co-injected, their ratio was fixed to 1:1:1
and the total dose was 6 × 10
6 infection unit (iu) per rat.
In cases where two viral vectors were co-injected, their
ratio was fixed to 1:4 and the total dose was also 6 × 10
6
iu per rat. The injection rate was 0.5 μl/min and the injec-
tion needle was allowed to remain in situ for 5 min before
being slowly retracted at the end of each injection. Dox
was administered at a concentration of 2 mg/ml supple-
mented with 5% sucrose in the animals’ drinking water as
required. Seven days postinjection, rats were terminally
anaesthetized (sodium pentobarbital, 100 mg/kg intramus-
cularly) and perfused through the heart with 0.1 M PBS
(pH 7.4). For Luc activity assays, the brain tissue samples
were removed and stored at -80°C until processing. After
adding PBS buffer (100 μl PBS per 50 mg tissue), each
sample was homogenized by sonication for 10 sec on ice,
and then centrifuged at 13000 rpm at 4°C. In total, 10 μl
of the supernatant at room temperature was used for the
Luc activity assay. For nNOS western blot analysis, the
brain tissue samples were removed and immediately
homogenized with a manual homogenizer in RIPA buffer
containing protease inhibitor cocktail. Total protein
extracts were then kept at -80°C until further processing.
Luciferase assay
Luciferase assay was performed with a luciferase assay
kit (Promega) in a single-tube luminometer as described
[29]. The results are expressed in relative light units
(RLU) per well of a 24-well plate for in vitro experi-
ments or per rat region for in vivo experiments. Data
are expressed as the mean ± standard deviation.
Western blot analysis
The nNOS western blot analysis was carried out as pre-
viously described [30]. Briefly, total protein was
extracted from homogenized samples, followed by
quantification with a BCA protein assay kit (Pierce).
20 μg of total protein per lane were separated on
NuPAGE 4-12% Bis-Tris gels (Invitrogen) and trans-
ferred to PVDF membranes (Millipore). The membranes
were blocked in 5% non-fat dry milk (NFDM) in Tris-
buffered saline with 0.1% tween-20 (TBST) for 45 min,
and incubated with polyclonal rabbit anti-nNOS anti-
body (Zymed) at 1:5000 in 3% NFDM-TBST or mono-
clonal anti-beta-actin antibody (Sigma) at 1:5000 in 1%
BSA-TBST overnight. Following incubation with poly-
clonal swine anti-rabbit immunoglobulins/HRP (Dako)
at 1:5000 in 3% NFDM-TBST or polyclonal rabbit anti-
mouse immunoglobulins/HRP (Dako) at 1:10000 in 1%
BSA-TBST for 90 min, the immunoreactions were
detected with an Immun-Star Western chemilumines-
cent kit (Bio-Rad) and Amersham high performance
autoradiography film (GE Healthcare). Scion Image soft-
ware (Scion Corporation) was used to quantitatively
compare the relative blot intensities.
Northern blot analyses
Total RNA was isolated from rat tissues seven days
post-injection using mirVana Isolation Kit (Ambion).
Fifteen micrograms total RNA were fractionated on a
15% denaturing polyacrylamide gel and blotted onto
Hybond-XL membrane (Amersham). RNA was immobi-
lized by UV crosslinking and baking for 1 hour at 80°C.
Hybridization was carried out at 42°C using UltraHyb-
Oligo Hybridization buffer (Ambion). Probes were
labeled with
32P using T4 polynucleotide kinase (New
England Biolabs). Membranes were washed twice in
2xSSC, 0.1% SDS and 0.2xSSC, 0.1% SDS at 37°C and
exposed to film. Scion Image software (Scion Corpora-
tion) was used to quantitatively compare the relative
blots intensities.
Real time RT-PCR
Total RNA was isolated from cell lines and rats using
RNAqueous-Micro kit (Ambion) and treated with
DNase I. RNA purity was verified by performing PCR
on samples not treated with reverse transcriptase. Real-
time RT-PCRs were carried out using a DNA Engine
Opticon 2 system (MJ Research) and the QuantiTect
SYBR Green RT-PCR kit (Qiagen), as described [31].
Expression of target genes was assessed in relation to a
housekeeping gene (b-actin) using the comparative Pfaffl
method [ratio = (Etarget)
ΔCT target (control-treated)/(Eref)
ΔCT
ref(control-treated)] in each sample [32]. Fold differences
against DVC were calculated (n = 5). PCR primers for
rat Dicer, Argonaute proteins (Ago), Digeorge syndrome
critical region gene 8 (DGCR8), Exportin 5 and Drosha
were designed according to sequence information
provided by NCBI with the accession numbers:
XM_001069041, XM_001058231, NM_001105865,
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Among the above, XM_001069041 for Dicer and
XM_001058231 for Ago are predicted sequences by
automated computational analysis using gene prediction
method: GNOMON, supported by mRNA and EST evi-
dence. Primer sequences are detailed in the Additional
file 1.
Results
Combinations of vectors used in this study
Ten different viral combinations were used here. To
simplify the presentation, we used abbreviations. Combi-
nations and abbreviations are presented in Table 1.
Analyses of the functions of miR30-shRNA/Luc in vitro
First, the effect of miR30-shRNA/Luc was assessed in
cell lines. PC12 cells were co-transduced with viral com-
binations of LVVs-miRLuc-control1 and LVVs-miRLuc-
neurone while 1321N1 cells were co-transduced with
LVVs-miRLuc-control2 and LVVs-miRLuc-glia. In the
absence of Dox, Luc expression from LVVs-miRLuc-
neurone [Figure 2(a), group B] was significantly knocked
down by 80% as compared to that from LVVs-miRLuc-
control1 [Figure 2(a), group A] [5.37 × 10
5 ±9 . 2 5×1 0
4
vs 2.8 ×10
6 ±2 . 6 7×1 0
5 RLU per well; P < 0.01] in
PC12 cells. Similarly, in 1321N1 cells, Luc expression
from LVVs-miRLuc-glia [Figure 2(b), group B’]w a ss i g -
nificantly reduced by 90% as compared to that from
LVVs-miRLuc-control1 [Figure 2(b), group A’]( 4 . 7 9×
10
4 ±6 . 5 4×1 0
3 vs 4.85 × 10
5 ±1 . 8 1×1 0
4 RLU per
well; P < 0.01). The Luc knock-down was completely
prevented in the presence of Dox in both PC12 and
1321N1 cells [Figure 2(a), group C vs B and Figure 2(b),
group C’ vs B’]. The inhibitory effect of Dox disappeared
after three days of Dox withdrawal [Figure 2(a), group D
vs C and Figure 2(b), group D’ vs C’]. These results
demonstrate that bidirectional transcriptionally ampli-
fied SYN and GfaABC1D promoters provide a sufficient
level of tTA to activate the Tretight promoter which
then drives the synthesis of GFP-miR30-shRNA/Luc
transcript to induce substantial Luc knock-down.
Of note, the astrocytic system LVVs-miRLuc-glia was
more effective than the neuronal system, LVVs-miRLuc-
neurone. We therefore tested whether this could reflect a
higher efficacy of the amplification strategy when applied
to the GfaABC1D as compared to SYN promoter. To this
end, we performed a real time PCR analysis of tTA
expression level from LV-mCMV/GfaABC1D-tTA in
Table 1 Viral combinations used in this study and their functions
Abbreviation Vector combination Function
LVVs-miRLuc-
neurone
LV-SYN-Luc
+ LV-Tretight-GFP-miR30-shRNA/Luc
+ LV-mCMV/SYN-tTA
Neurone-specific Luc knock-down system. Tet-off transactivator tTA is expressed from
LV-mCMV/SYN-tTA which contains the bidirectional amplified SYN promoter to ensure
high level of tTA. tTA binds to Tretight promoter in LV-Tretight-GFP-miR30-shRNA/Luc
and activates the expression of shRNA/Luc.
LVVs-miRLuc-glia LV-GfaABC1D-Luc
+LV-Tretight-GFP-miR30-shRNA/Luc
+LV-mCMV/GfaABC1D-tTA
Astrocyte-specific Luc knock-down system. Transactivator tTA is expressed from LV-
mCMV/GfaABC1D-tTA which contains the bidirectional amplified GfaABC1 D promoter
to ensure high level of tTA. tTA binds to Tretight promoter in LV-Tretight-GFP-miR30-
shRNA/Luc and activates the expression of shRNA/Luc.
LVVs-miRLuc-
control1
LV-SYN-Luc
+ LV-Tretight-GFP-miR30-shRNA/Luc
+ LV-SYN-WPRE
Control combination used in Luc knock-down experiments for the neurone-specific
system. Since there is no tTA expression in this combination, shRNA/Luc will not be
expressed. So this combination marked the background expression level of Luc driven
by SYN promoter.
LVVs-miRLuc-
control2
LV-GfaABC1D-Luc
+ LV-Tretight-GFP-miR30-shRNA/Luc
+ LV-GfaABC1D-WPRE
Control combination used in Luc knock-down experiments for the astrocyte-specific
system. Similar as LVVs-miRLuc-control 1, there is no tTA expression in this
combination; shRNA/Luc will not be expressed. Therefore this combination marked the
background expression level of Luc driven by GfaABC1 D promoter.
LVVs-miRnNOS-
neurone
LV-Tretight-GFP-miR30-shRNA/nNOS
+ LV-mCMV/SYN-tTA
Neurone-specific nNOS knock-down system. Mechanism is similar as LVVs-miRLuc-
neurone.
LVVs-miRnNOS-glia LV-Tretight-GFP-miR30-shRNA/nNOS
+ LV-mCMV/GfaABC1D-tTA
Astrocyte-specific Luc knock-down system. Mechanism is similar as LVVs-miRLuc-glia.
LVVs-miRnNOS-
control1
LV-Tretight-GFP-miR30-shRNA/nNOS
+ LV-SYN-WPRE
Control combination used in nNOS knockdown experiments for the neurone-specific
system. Mechanism is similar as LVVs-miRLuc-control1.
LVVs-miRnNOS-
control2
LV-Tretight-GFP-miR30-shRNA/nNOS
+ LV-GfaABC1D-WPRE
Control combination used in nNOS knockdown experiments for the astrocyte-specific
system. Mechanism is similar as LVVs-miRLuc-control2.
LVVs-miRnNOS-
negative control1
LV-Tretight-GFP-miR30-shRNA/Luc
+ LV-mCMV/SYN-tTA
Negative control combination used in nNOS knock-down experiments for the
neurone-specific system. Instead of producing shRNA/nNOS it produces shRNA/Luc
which shouldn’t work on nNOS knockdown.
LVVs-miRnNOS-
negative control2
LV-Tretight-GFP-miR30-shRNA/Luc
+ LV-mCMV/GfaABC1D-tTA
Negative control combination used in nNOS knock-down experiments for the
astrocyte-specific system. Instead of producing shRNA/nNOS it produces shRNA/Luc
which shouldn’t work on nNOS knockdown.
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compared to LV-GfaABC1D-tTA and LV-SYN-tTA
respectively. LV-mCMV/GfaABC1D-tTA increased tTA
expression 14.5 fold as compared to LV-GfaABC1D-tTA
while LV-mCMV/SYN-tTA increased 7.6 fold as com-
pared to LV-SYN-tTA (data not shown). Thus, higher
efficacy of the astrocytic system is likely to reflect a
higher level of tTA in glial cells and therefore a higher
expression of the gene knock-down cassette.
Analysis of the effects of miR30-shRNA/Luc in vivo
Next we investigated the effect of miR30-shRNA/Luc in
vivo. LVVs-miRLuc-neurone, LVVs-miRLuc-glia and the
corresponding control vectors were injected into the
DVC and HIP of adult rats. As shown in Figure 3a(1), in
the absence of Dox, LVVs-miRLuc-neurone (Figure 3a,
group B) suppressed DVC neuronal Luc expression by
50% as compared to the level achieved using LVVs-miR-
Luc-control1 (Figure 3a, group A) (1.85 × 10
6 ±4 . 5 8×
10
5 vs 3.77 × 10
6 ±3 . 7 0×1 0
5 RLU per DVC, P < 0.01).
LVVs-miRLuc-glia (Figure 3a, group B’) suppressed DVC
glial Luc expression even more dramatically (Figure 3a
~85%) as compared to level of expression using LVVs-
miRLuc-control2 (Figure 3a, group A’) (3.69 × 10
6 ±4 . 5 4
×1 0
5 vs 2.37 × 10
7 ± 5.71 × 10
6 RLU per DVC, P < 0.01).
This was most likely due to a higher potency of LV-
mCMV/GfaABC1D-tTA as compared to LV-mCMV/
SYN-tTA as revealed by real time PCR analysis of tTA
expression from our in vitro work (see previous section).
In both cell types, the knock-down could be completely
blocked by administration of Dox into the drinking water
[group C in Figure 3a(1); group C’ in Figure 3a(2)]. We
then tested whether gene knock-down in DVC is indeed
cell-specific. To do this, we injected the neurone-targeted
gene knock-down system (LV-mCMV/SYN-tTA + LV-
Tretight-GFP-miR30-shRNA/Luc) with LVV to express
Luc in astrocytes (LV-GfaABC1D-Luc) and, conversely,
the astrocyte-targeted knock-down system (LV-mCMV/
GfaABC1D-tTA+ LV-Tretight-GFP-miR30-shRNA/Luc)
together with LVV for neuronal Luc expression
(LV-SYN-Luc). No knock-down occurred in either case
(see Additional file 2) confirming a high degree of cell-
specificity of this effect.
Surprisingly, much weaker Luc knock-down was
observed using both the neurone-specific and the astro-
cyte-specific systems, LVVs-miRLuc-neurone and LVVs-
miRLuc-glia in HIP compared to DVC [Figure 3b(1), B
vs A; Figure 3b(2), B’ vs A’ ]. Reduction in Luc levels
with neuronal system was ~ 27% (5.5 × 10
4 ±1 . 6 4×
10
4 vs 7.52 × 10
4 ± 2.48 × 10
4 RLU per HIP) and ~ 35%
with the astrocytic system (6.32 × 10
5 ±2 . 4 3×1 0
5 vs
9.65 × 10
5 ±3 . 2 0×1 0
5 RLU per HIP). Neither effect
was significant (P > 0.05), although the trend was clear
in both cases.
nNOS gene knock-down in vitro and in vivo
While Luc knock-down is technically convenient it is an
artificial approach as this gene is not expressed in the
mammalian brain. Thus, it was important to demon-
s t r a t ew h e t h e ra ne n d o g e n o u sg e n ei sa sp r o n et o
knock-down as an exogenously expressed transcript. We
chose nNOS since this protein is abundantly expressed
in both DVC and HIP (Figure 4 and [22-25]).
We first confirmed the efficacy of the anti-nNOS
construct, LV-Tretight-GFP-miR30-shRNA/nNOS in
PC12 and 1321N1 cells. An adenoviral vector (AD)
AD-CMV-nNOS was used to induce high level of
nNOS expression in both PC12 and 1321N1 cells since
there are almost no endogenous nNOS expression in
these two cell lines (unpublished observation). As
Figure 2 Analyses of the functions of miR30-shRNA/Luc in
vitro. (a) LV-mCMV/SYN-tTA and (b) LV-mCMV/GfaABC1D-tTA
mediated Dox-controllable Luc knock-down in PC12 cells and
1321N1 cells. Dox was used at a concentration of 200 ng/ml. - Dox,
cells were cultured in the continuous absence of Dox; + Dox, cells
were cultured in the continuous presence of Dox; + - Dox, Dox was
administered for 48 h during and after transduction followed by a
change to Dox-free medium and culturing for three more days. The
results are expressed in RLU per well. A: LVVs-miRLuc-control1; B, C,
D: LVVs-miRLuc-neurone A’: LVVs-miRLuc-control2; B’,C ’,D ’: LVVs-
miRLuc-glia. *P < 0.01, **P = 0.06, compared with group A. ♦P <
0.01, ♦♦P = 0.84, compared with group A’. In this and the following
figures the error bars represent standard deviation.
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Page 6 of 11shown in Figure 4 in the absence of Dox, both LVVs-
miRnNOS-neurone and LVVs-miRnNOS-glia markedly
knocked down nNOS in PC12 cells (~ 69% reduction
in optical density, treatment 2 vs treatment 1, Figure
4a) and 1321N1 (~ 82% reduction, treatment 2 vs
treatment 1, Figure 4b). This nNOS knock-down effect
could be prevented by Dox (treatment 3 in Figure 4a
and Figure 4b). It is important to note that anti-Luc
construct, LV-Tretight-GFP-miR30-shRNA/Luc (treat-
ment 4 in Figure 4a and Figure 4b), was without effect
in either cell line, indicating that the nNOS knock-
down was sequence-specific.
Figure 3 Analyses of the efficacy of miR30-shRNA/Luc in vivo in adult rat brain. a: (1) LV-mCMV/SYN-tTA and (2) LV-mCMV/GfaABC1D-tTA
mediated Dox-controllable Luc knock-down in DVC in rats. b: (1) LV-mCMV/SYN-tTA and (2) LV-mCMV/GfaABC1D-tTA mediated Dox-controllable
Luc knock-down in HIP in rats. Rats in groups A, A’, B and B’ were not treated with Dox. Rats in groups C and C’ drank Dox-containing water
post-injection for 7 days. There were 3 rats in each group. A: LVVs-miRLuc-control1; B, C: LVVs-miRLuc-neurone; A’: LVVs-miRLuc-control2; B’,C ’:
LVVs-miRLuc-glia. *P < 0.01, **P = 0.18, compared with group A. ♦P < 0.01, ♦♦P = 0.48, compared with group A’. ￿P = 0.12, ￿￿P = 0.23, compared
with group A. ♠P = 0.03, ♠♠P = 0.17, compared with group A’.
Figure 4 Western-blot analyses of the functions of miR30-shRNA/nNOS both in vitro (a, b) and in vivo (c, d).a :In vitro tests in PC12 cells.
- Dox, cells were cultured in the continuous absence of Dox; + Dox, cells were cultured in the continuous presence of Dox; 1: AD-CMV-nNOS +
LVVs-miRnNOS-control1; 2, 3: AD-CMV-nNOS+ LVVs-miRnNOS-neurone; 4: AD-CMV-nNOS+ LVVs-miRnNOS-negative control1; 5: mock transfection.
b: In vitro tests in 1321N1 cells. 1: AD-CMV-nNOS + LVVs-miRnNOS-control2; 2, 3:AD-CMV-nNOS + LVVs-miRnNOS-glia; 4: AD-CMV-nNOS + LVVs-
miRnNOS-negative control2 5’: mock transfection. c, d: In vivo tests in DVC (c) and HIP (d) in rats. Rats in groups 2, 4, were not treated with Dox.
Rats in group 3 drunk Dox-containing water post-injection for 7 days. There were 3 rats in each group. 1: mock infection; 2, 3: LVVs-miRnNOS-
neurone; 4: LVVs-miRnNOS-negative control2.
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Page 7 of 11A substantial nNOS knock-down (~ 55% reduction)
(treatment 2 vs treatment 1, Figure 4c) was observed
when LVVs-miRnNOS-neurone was injected into DVC
in vivo and consistent with the in vitro data this knock-
down could be fully prevented by Dox (treatment 3).
However, similar to the experiment with Luc, the nNOS
knock-down in HIP (~ 35% reduction; treatment 2 vs
treatment 1, Figure 4d) was noticeably weaker. Again,
the anti-Luc construct LV-Tretight-GFP-miR30-shRNA/
Luc (treatments 4 in Figure 4c and Figure 4d) did not
trigger nNOS knock-down.
Analysis of miRNA processing enzyme expression in DVC
and HIP
We were surprised to find that the same knock-down
cassettes driven by the same targeting systems behaved
differently when applied to DVC as compared to HIP.
To examine whether the different RNAi efficiency in
DVC and HIP is caused by different processing of
RNAi, we performed northern blotting analysis to assess
the ratio between mature-RNAi and precursor-miR30-
RNAi in these two regions. We found higher ratio for
b o t hL u cR N A ia n dn N O SR N A if r o mD V Cr e l a t i v et o
that from HIP (Figure 5). The ratios of mature RNAi to
unprocessed from LVVs-miRLuc-neurone injected rats
are ~1:1 in HIP and ~ 18:1 in DVC respectively. With
LVVs-miRnNOS-neurone, the ratios are ~ 1.3:1 in HIP
and ~ 23.5:1 in DVC respectively. We then hypothesized
that variations in the composition of the RNAi machin-
ery are a likely cause of this site-specific difference in
RNAi processing. To test this idea, we conducted real
time RT-PCR analysis of 5 key enzymes implicated in
miRNA biogenesis, namely Drosha, DGRC8, Exportin-5,
Dicer and Argo (Figure 6a). All five genes tested were
f o u n di nb o t hD V Ca n dH I Pa n dt h e i re x p r e s s i o ni n
HIP was marginally higher than in DVC. Thus, lower
gene knock-down efficacy in HIP is unlikely to be
related to regional differences in the availability of the
key components on miRNA pathway between DVC and
HIP (Figure 6b).
Discussion
This study was designed to address two questions.
Firstly, we wanted to test the efficacy of Pol II-based
cell-type specific and Dox-controllable gene knock-
down in the brain. Secondly, we wanted to find
out whether the same knock-down system should be
expected to operate with equal effectiveness in different
parts of the CNS. The reason for posing this question is
that the lower parts of the CNS, such as medulla oblon-
gata, differ from the higher brain in many respects,
including their cellular composition, embryonic origins
and gene expression patterns. Neither of these questions
has been addressed previously. Moreover, we wanted to
assess the effect at the protein level rather than mRNA
content since it remains unclear how these two readouts
of gene expression are affected by different RNAi con-
structs, many of which are also thought to operate via
translational repressionr a t h e rt h a nt h r o u g hm R N A
degradation.
Lentiviral systems developed in the course of this
study enable tight Dox-controllable and cell-specific
miR30-based RNAi gene knock-down. Using the Tet
system in these designs bring additional benefits because
it not only allows switching off the knock-down effect
but also simplifies re-targeting of the knock-down vector
to different cell types, provided that a sufficiently cell
type specific promoter is available. For the Tet system
to operate it is essential to achieve high levels of Tet
transactivator expression. Mammalian cell-specific pro-
moters are seldom sufficiently powerful, so we have
used the previously validated bidirectional TSTA [26] to
enhance two such weak promoters here: the SYN and
GfaABC1D. Interestingly, the degree of enhancement
achieved using the same bidirectional TSTA strategy
was higher for GfaABC1D as indicated by a much higher
increase in tTA transcription from enhanced GfaABC1D
compared to enhanced SYN (see results Analyses of the
functions of miR30-shRNA/Luc in vitro). This correlated
with the overall higher efficacy of gene knock-down
achieved with the astrocyte-targeted system both in
vitro and in vivo than the neuronal specific system.
Our experiments show that at least in the DVC we
can expect a very significant knock-down of the target
protein (~ 55%) with our approach. The efficacy of
knock-down seems to correlate with the power of the
vector used to express the tTA, making astrocytic sys-
tem slightly more potent than the neuronal one. It is
clear that there is no cross-talk between neurone- and
Figure 5 Northern blot analyses to assess the processing of
RNAi in HIP and DVC. Total RNA samples were isolated from rats
injected with LVVs-miRLuc-neurone (upper half) or LVVs-miRnNOS-
neurone (lower half) into HIP and DVC. Blots were probed for either
Luc or nNOS shRNA transcripts.
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Page 8 of 11astrocyte-targeted knock-down since when Luc is placed
in the phenotype not targeted by the knock-down vec-
tors there is no decrease in expression (see Additional
file 2). This also strongly argues against the involvement
of any non-specific factors such as local interferon
induction. Removal of the knock-down response by Dox
(Figures 2, 3 and 4) is another argument for the specific
nature of this effect.
Both Pol II and Pol III promoters have been used to
express shRNA for RNAi [33]. Unlike most small cellu-
lar RNAs, miRNAs are primarily transcribed by Pol II,
which may reflect a need for more moderate, regulatable
and cell-specific expression. In the context of this study,
the Pol II driven production of miRNA-based shRNA
allows cell-specific knock-down and exogenous control
using the Tet-system. In addition, Pol II promoters in
miRNA-based RNAi systems have no strict require-
ments for the transcriptional start site and termination
signal so theoretically various Pol II promoters can be
used [2,9,34]. Insertion of a GFP reporter gene upstream
of miR-shRNAs is thought to have at least two advan-
tages. Firstly, this allows monitoring of the shRNA pro-
duction in individual cells. Indeed we have noticed GFP
expression in our experiments (data not shown). Sec-
ondly, the expression of miR-shRNAs and protein
mRNAs in a monocistronic transcript could lead to
both effective processing of the miR-shRNAs and trans-
lation of protein from the mRNA [15,35,36].
It is important to realize that when Luc was used as a
target, vectors to express Luc and the knock-down
LVVs were applied together as a mixture. While they
should have been internalized by the same population of
cells in the target area it is possible that some cells
would only take in one or two vectors, but not all three.
Therefore, a possibility is that some of the residual Luc
expression comes from those cells where the binary
knock-down system was absent or did not assemble in
full (for example, no LVV to express Tre was interna-
lized). When nNOS is chosen as a target, the protein
can only come from the cells which endogenously
express it in the target area. It is likely that the level of
most endogenous genes will be less than those
e x p r e s s e de x o g e n o u s l yb yaL V V .T h i sc o u l db eo n eo f
the reasons why nNOS knock-down was evident not
only in DVC (as was the case for Luc) but also in HIP
(Figure 4c and 4d) although Luc knock-down was only
evident as a trend in HIP (Figure 3b).
To our knowledge, this is the first study to evaluate
the different efficacies of miR30-based RNAi system
among different regions in the brain in vivo.A tp r e s e n t
we do not know what accounts for this difference. We
hypothesized that lower efficacy of the tested constructs
in HIP compared to DVC was a result of a lower level
of expression of the components involved in the RNAi
pathway. However, real-time RT-PCR analysis of Dicer,
Argonaute, DGRC8, Exportin 5 and Drosha revealed
Figure 6 Model for miRNA biogenesis and real time PCR analysis of the five key enzymes implicated in miRNA biogenesis. a: Model for
miRNA biogenesis. miRNA genes are transcribed by Pol II to generate the primary transcripts (pri-miRNAs). The initiation step (cropping) is
mediated by the Drosha-DGCR8 complex. The product of the nuclear processing is ~ 70-nt pre-miRNA. This structure can serve as a signature
motif that is recognized by the nuclear export factor Exportin-5. Pre-miRNA constitutes a transport complex together with Exportin-5 and its
cofactors. Upon export, the cytoplasmic RNase III Dicer participates in the second processing step (dicing) to produce miRNA duplexes (~ 22-nt).
The duplex is recognized by the PAZ domain of the Ago protein and incorporated into RISC. Usually one strand is selected as the mature
miRNA, whereas the other strand is degraded. b: Real time PCR analyses of the expression levels of DGCR8, Drosha, Exportin-5, Dicer and Ago in
DVC and HIP in rats (n = 5). The value for DVC was set as one.
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Page 9 of 11slightly higher levels of all of these transcripts in HIP
than in DVC. Hence, other untested or unknown com-
ponents must account for the difference. RNAi is a
dynamic process and its machinery depends on multiple
components with only poorly characterized expressions
patterns [37]. Moreover, novel components involved in
posttranscriptional gene silencing are very likely to
emerge. Accumulating evidence indicates that many
miRNAs show distinct expression patterns in an organ
or tissue-specific way [37-39]. Our constructs, following
the design of Stegmeir et al. used flanking and loop
sequences from an endogenous miR30 [37]. A recent
study uncovered 44 miRNAs which exhibited marked
differences in the level of expression between spinal
cord, cerebellum and hippocampus in the adult mouse
[40]. For example, miR-195, miR-497, and miR-30b
were found to be enriched in the cerebellum whereas
miR-218, miR-221, miR-222, miR-26a, miR-128a/b,
miR-138 and let-7c were highly expressed in the HIP.
Unfortunately, the DVC was not studied specifically. It
is not impossible that in the brain there are not only
regional differences in the levels of expression of the
miRNAs but also of some other factors which favour
the the production and maturation of specific miRNA.
If that was the case, processing of knock-down con-
s t r u c t sb u i l tu s i n ge l e m e n t so fs o m em i R N A sc o u l db e
more efficient in some parts of the brain than in others
as we have found herein. This should be kept in mind
for loss-of function studies in the rat brain.
In summary, we have demonstrated that efficient, cell-
specific and Dox-controllable gene knock-down can be
achieved in the rat brain although the potency of the
knock-down using the same construct may differ in dif-
ferent parts of the CNS. This efficient gene silencing
system will be a valuable resource for basic gene func-
tion study and potentially, for the development of gene-
based therapeutics of the CNS. While this manuscript
was under review, a study where we have used the sys-
tem for neurone-specific knock-down of nNOS was
published [41], demonstrating the practical value of this
approach. In that study we demonstrated that nNOS
plays a key role in several pathological processes trig-
gered in motor neurones by axotomy. Critically, the
knock-down in that experiment was performed in the
same brainstem area where, as we show here, this type
of RNAi has proven to be most effective. Commercial
availability of miRNA-like hairpins might create a feeling
that any such construct may be used with the same
effect in any part of the brain. This study therefore
alerts the readers to avoid such an assumption when
planning loss-of function studies in the rodent brain. It
also illustrates the fact that more research is needed to
perfect and optimise the current strategies for RNAi-
mediated gene knock-down in vivo.
Conclusions
Selective gene knock-down in subsets of brain cells is
achievable; however, there are some presently unknown
regional factors which affect either the processing of
miRNA-based cassettes ort h e i rp o t e n c yf o rg e n e
silencing.
Additional material
Additional file 1: Table S1. Primers used for real time PCR. Primer
sequences used in the real time PCR analysis of five key enzymes
implicated in miRNA biogenesis including DGCR8, Drosha Exportin 5,
Dicer and Argonaute proteins in rats.
Additional file 2: Figure S1 Neurone- and astrocyte-targeted knock-
down is cell-type specific. LV-mCMV/SYN-tTA and LV-mCMV/GfaABC1D-
tTA mediated luciferase knock-down is cell-type specific. a: LV-mCMV/
GfaABC1D-tTA controlled miR30-shRNA/Luc didn’t knockdown Luc
expression in neurones. b: LV-mCMV/SYN-tTA controlled miR30-shRNA/
Luc didn’t knockdown Luc expression in glia. A: LVVs-miRLuc-control1; B:
LV-SYN-Luc + LV-Tretight-GFP-miR30-shRNA/Luc + LV-mCMV/GfaABC1D-
tTA. A’: LVVs-miRLuc-control2; B’: LV-GfaABC1D-Luc + LV-Tretight-GFP-
miR30-shRNA/Luc + LV-mCMV/SYN-tTA.
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